Standing near Shasqi Inc.’s cancer research conference poster about its use of bioorthogonal chemistry in April 2022, company founder and CEO José Mejía Oneto was approached by an attendee from the large drug company Johnson & Johnson, leading eventually to an Oct. 5 meeting between the companies.
